Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.43 |
| ▸ | HTR1A | P08908 | 7/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344890 | 0.78 | TTR (0.44) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL6194571 | 0.78 | HTR1A (0.58) | HTR7HTR1AHTR6HTR2BHTR1B | |
| SCHEMBL8226241 | 0.74 | NOTUM (0.56) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL4909469 | 0.74 | HTR7 (0.58) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL8226246 | 0.73 | PIM1 (0.48) | HTR7ALDH1A1 | |
| SCHEMBL8220981 | 0.73 | POLB (0.50) | HTR7HTR1AHTR6HTR2BADRB1 | |
| SCHEMBL8221004 | 0.71 | KMT2A (0.48) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL8229627 | 0.71 | MAPT (0.47) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL29893068 | 0.71 | KDR (0.53) | HTR7HTR1AHTR6HTR2BHTR1D | |
| SCHEMBL5280641 | 0.71 | KDR (0.53) | HTR7HTR1AHTR6HTR2BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HTR7 36/4885HTR1A 13/4885HTR6 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.